BioWorld

Jan. 14, 2002

View Archived Issues

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Same Gene Inflicts Both Axonal And Demyelinating Versions Of Charcot-Marie-Tooth Neuropathy

Antigenics Raises $60M From Shelf For Oncophage Trials

Novo Ends Deal With Flamel, Flamel Signs Deal With Servier

Other News To Note

U.S. Patent Disclosures

Dendreon Falls On Provenge Phase III Interim Analysis Results

Poor interim statistical analysis of a Phase III trial of Provenge in prostate cancer patients caused Seattle-based Dendreon Corp.'s stock to dive Friday. Read More

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...